en · de · es
selank-notes.peptides3626.com › Info › Background And Molecular Identity — Beginner to Advanced

Background And Molecular Identity — Beginner to Advanced

By Editorial Desk · published 2025-12-29 · last reviewed 2026-01-28 · Info

The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-01-28 and is reviewed periodically as new material appears.

Background and Molecular Identity

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Selank Background And Chemical Identity

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideTuftsin analogue with a C-terminal Pro-Gly-Pro tail
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProAbbreviated TKPRPGP in most catalogues
Molecular massAbout 752 DaValue for the free peptide
SolubilityFreely soluble in waterAqueous solutions are kept cold and used promptly
Typical storage-20 °C, dry, protected from lightApplies to the lyophilised powder before reconstitution

Analytical Methods and Material Handling

Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.

Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.

Related pages on this site

Identity and Structural Background

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Reference notes

==== September ==== On 1 September, the National Guard attacked the Walgha, Al-Majdal and Al-Mazraa fronts with a drone, then the Internal Security Forces clashed with the National Guard, leaving 10 members of the Internal Security Forces injured, conversely, the National Guard claimed that the Internal Security Forces launched mortar rounds and fired machine guns. On 4 September, groups considered as "outlaws" forced the expulsion of Atef Hneidi, known as "al-Basha", from the Suwayda governorate, this comes after Atef Hneidi issued a statement criticizing Hikmat al-Hijri. On 6 September, clashes broke out between the National Guard and the Syrian government forces, in the villages of Rima Hazem and Al-Mansoura, involving the use of heavy machine guns. On 10 September, Syrian state television reported that "criminal groups" blocked the al-Matouna checkpoint, meanwhile, a source in Suwayda claimed that Syrian internal security forces stationed in al-Matouna blocked the passage of tourists to Damascus without any explanation. On 24 September, Syrian government forces opened fire with machine guns on the city of Suwayda, and the National Guard responded to the attacks.

=== Civil and criminal proceedings === In March 2018, the US Securities and Exchange Commission filed civil fraud charges against Theranos, its CEO Holmes and former president Ramesh "Sunny" Balwani, claiming they had engaged in an "elaborate, years-long fraud" wherein they "deceived investors into believing that its key product – a portable blood analyzer – could conduct comprehensive blood tests from finger drops of blood". Holmes reached a settlement with the SEC which required her to pay $500,000, forfeit 19 million shares of company stock, and be barred from having a leadership position in any public company for ten years. Balwani did not settle with the SEC. On June 15, 2018, Holmes and Balwani were indicted on multiple counts of wire fraud and conspiracy to commit wire fraud. According to the indictment, investors, doctors and patients were defrauded. It is alleged that the defendants were aware of the unreliability and inaccuracy of their products, but concealed that information. The case, United States v. Elizabeth A. Holmes, et al., was assigned to Lucy H. Koh, United States district judge of the United States District Court for the Northern District of California. The jury selection for the trial was to begin on July 28, 2020, and the trial was to have commenced in August 2020; however, the COVID-19 pandemic led to a proposed October date, before the trial for Holmes was rescheduled to begin on August 31, 2021, with Balwani's trial pushed back further to 2022.

End groups are an important aspect of polymer synthesis and characterization. In polymer chemistry, they are functional groups that are at the very ends of a macromolecule or oligomer (IUPAC). In polymer synthesis, like condensation polymerization and free-radical types of polymerization, end-groups are commonly used and can be analyzed by nuclear magnetic resonance (NMR) to determine the average length of the polymer. Other methods for characterization of polymers where end-groups are used are mass spectrometry and vibrational spectrometry, like infrared and raman spectroscopy. These groups are important for the analysis of polymers and for grafting to and from a polymer chain to create a new copolymer. One example of an end group is in the polymer poly(ethylene glycol) diacrylate where the end-groups are circled.

Sources: en.wikipedia.org

Notes from published material

== Side effects == Like any form of radiotherapy, ionising radiation can harm healthy tissue as well as the intended treatment target. Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium (177Lu) oxodotreotide.

Biocatalyzed kinetic resolution is utilized extensively in the purification of racemic mixtures of synthetic amino acids. Many popular amino acid synthesis routes, such as the Strecker Synthesis, result in a mixture of R and S enantiomers. This mixture can be purified by (I) acylating the amine using an anhydride and then (II) selectively deacylating only the L enantiomer using hog kidney acylase. These enzymes are typically extremely selective for one enantiomer leading to very large differences in rate, allowing for selective deacylation. Finally the two products are now separable by classical techniques, such as chromatography.

In the Borexino Counting Test Facility, a 14C/12C ratio of 1.94×10−18 was determined; probable reactions responsible for varied levels of 14C in different petroleum reservoirs, and the lower 14C levels in methane, have been discussed by Bonvicini et al.

229Th has a nuclear isomer, 229mTh, with an excitation energy of 8.355733554021(8) eV. This is by far the lowest of all nuclear isomers. Because this energy lies between thorium's first and second ionization energies of 6.3 and 11.5 eV, the decay rate of 229mTh is sensitive to the electronic environment of the nucleus. In neutral 229mTh, the isomer decays by internal conversion to 229Th+ within a few microseconds. However, the isomeric energy is not enough to remove a second electron, so internal conversion is impossible in 229mTh+ ions; they are forced to decay radiatively with a half-life 8.4 orders of magnitude longer, in excess of 1000 seconds. Embedded in ionic crystals, ionization is not quite 100%, so a small amount of internal conversion occurs, leading to a recently measured lifetime of ≈600 s, which can be extrapolated to a lifetime for isolated ions of 1740±50 s. Any photon emitted by nuclear decay is called a gamma ray, but this "gamma ray" has a frequency of 2020407384335±2 kHz (wavelength 148.3821828827(15) nm), in te far ultraviolet. This means it is possible to build a laser operating at this frequency, giving the only known opportunity for direct laser excitation of a nuclear state. This could have applications like a nuclear clock of very high accuracy or as a qubit for quantum computing. These applications were for a long time impeded by imprecise measurements of the isomeric energy, as laser excitation's exquisite precision makes it difficult to use to search a wide frequency range.

Sources: en.wikipedia.org

Background from the literature

People with MASLD often have no noticeable symptoms, and it is often only detected during routine blood tests or unrelated abdominal imaging or liver biopsy. In some cases, it can cause symptoms related to liver dysfunction such as fatigue, malaise, and dull right-upper-quadrant abdominal discomfort. Mild yellow discoloration of the skin may occur, although this is rare. MASH can severely impair liver function, leading to cirrhosis, liver failure, and liver cancer.

==== Target occupancy studies ==== Studies have estimated occupancy of target sites by trazodone based on trazodone concentrations in blood and brain and on the affinities of trazodone for the human targets in question. Roughly half of brain 5-HT2A receptors are blocked by 1 mg of trazodone and essentially all 5-HT2A receptors are saturated at 10 mg of trazodone, but the clinically effective hypnotic doses of trazodone are in the 25–100 mg range. The occupancy of the serotonin transporter (SERT) by trazodone is estimated to be 86% at 100 mg/day and 90% at 150 mg/day. Trazodone may almost completely occupy the 5-HT2A and 5-HT2C receptors at doses of 100 to 150 mg/day. Significant occupancy of a number of other sites may also occur. However, another study estimated much lower occupancy of the SERT and 5-HT2A receptors by trazodone.

AAS users tend to research the drugs they are taking more than other controlled-substance users; however, the major sources consulted by steroid users include friends, non-medical handbooks, internet-based forums, blogs, and fitness magazines, which can provide questionable or inaccurate information. AAS users tend to be unhappy with the portrayal of AAS as deadly in the media and in politics. According to one study, AAS users also distrust their physicians and in the sample 56% had not disclosed their AAS use to their physicians. Another 2007 study had similar findings, showing that, while 66% of individuals using AAS for non-medical purposes were willing to seek medical supervision for their steroid use, 58% lacked trust in their physicians, 92% felt that the medical community's knowledge of non-medical AAS use was lacking, and 99% felt that the public has an exaggerated view of the side-effects of AAS use. A recent study has also shown that long term AAS users were more likely to have symptoms of muscle dysmorphia and also showed stronger endorsement of more conventional male roles. A recent study in the Journal of Health Psychology showed that many users believed that steroids used in moderation were safe. AAS have been used by men and women in many different kinds of professional sports to attain a competitive edge or to assist in recovery from injury. These sports include bodybuilding, weightlifting, shot put and other track and field, cycling, baseball, wrestling, mixed martial arts, boxing, football, and cricket.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank chemically?

Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.

How does Selank relate to tuftsin?

Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.

Is Selank an approved medicine?

It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Network